|
|
 |
|
|
|
|
1. T. Teorell. Kinetics of distribution of substances administered to the body I. The extravascular modes of administration. Arch. Int. Pharmacodyn. 57: 205225, 1937. |
|
|
|
|
|
|
|
|
2. T. Teorell. Kinetics of distribution of substances administered to the body II. The intravascular modes of administration. Arch. Int. Pharmacodyn. 57: 226240, 1937. |
|
|
|
|
|
|
|
|
3. L. Z. Benet. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J. Pharm. Sci. 61: 536541, 1972. |
|
|
|
|
|
|
|
|
4. E. R. Garrett. The physicochemical and pharmacokinetic basis for the biopharmaceutical evaluation of drug biological activity in pharmaceutical formulations. Acta Pharmacol., Toxicol., 29: 129, 1971. |
|
|
|
|
|
|
|
|
5. M. Gibaldi. Pharmacokinetics and clinical pharmacokinetics, 3rd edn. Lea and Febiger, Philadelphia, 1984, p. 330. |
|
|
|
|
|
|
|
|
6. G. Levy and M. Gibaldi. Pharmacokinetics of drug action. Ann. Rev. Pharmacol. 12: 8598, 1972. |
|
|
|
|
|
|
|
|
7. J. C. K. Loo and S. Riegelman. New method for calculating the absorption rate of drugs. J. Pharm. Sci. 57: 918928, 1968. |
|
|
|
|
|
|
|
|
8. J. G. Wagner. Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, IL, 1975, p. 461. |
|
|
|
|
|
|
|
|
9. P. G. Welling. Role of pharmacokinetics in drug discovery and development. In Pharmacokinetics of Drugs. P. G. Welling and L. P. Balant, Eds. Springer-Verlag, Heidelberg, 1994, p. 5. |
|
|
|
|
|
|
|
|
10. A. Yacobi, J. P. Skelly, and V. K. Batra, Eds. Toxicokinetics and New Drug Development. Pergamon Press, New York, 1989, p. 246. |
|
|
|
|
|
|
|
|
11. P. G. Welling and F. A. de la Iglesia, Eds. Drug Toxicokinetics. Marcel Dekker, New York, 1993, p. 408. |
|
|
|
|
|
|
|
|
12. L. F. Chasseaud. Role of toxicokinetics in toxicity testing. In Drug Toxicokinetics. P. G. Welling and F. A. de la Iglesia, Eds. Marcel Dekker, New York, 1993, pp. 105142. |
|
|
|
|
|
|
|
|
13. A. M. Monro. Interspecies comparisons in toxicology: the utility and futility of plasma concentrations of the test substance. Regul. Toxicol. Pharmacol. 12: 137160, 1990. |
|
|
|
|
|
|
|
|
14. D. A. Smith. Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment. Eur. J. Drug Metab. Pharmacokin. 18: 3139, 1993. |
|
|
|
|
|
|
|
|
15. J.-L. Steimer, S. Vozeh, A. Racine-Poon, N. Holford, and R. O'Neill. The population approach: rationale, methods, and applications, in clinical pharmacology and drug development. In Pharmacokinetics of Drugs. P. G. Welling and L. P. Balant, Eds. Springer-Verlag, Heidelberg, 1994, p. 405451. |
|
|
|
|
|
|
|
|
16. K. T. Kivistö, P. Ojala-Karlsson, and P. J. Neuvonen. Inhibition of norfloxacin absorption by dairy products. Antimicrob. Ag. Chemother. 36: 489491, 1992. |
|
|
|
|
|
|
|
|
17. J. X. Sun, A. Cipriano, K. Chan, M. Klibaner, and V. A. John. Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. J. Pharm. Sci. 83: 264266, 1994. |
|
|
|
|
|
|
|
|
18. J. B. Dressman and K. Yamada. Animal models for oral drug absorption. In Pharmaceutical Bioequivalence. P. G. Welling, F. L. S. Tse, and S. V. Dighe, Eds. Marcel Dekker, New York, 1991, p. 235266. |
|
|
|
|
|